These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703 [TBL] [Abstract][Full Text] [Related]
3. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial. Heitz F; Marth C; Henry S; Reuss A; Cibula D; Gaba Garcia L; Colombo N; Schmalfeld B; de Gregorio N; Wimberger P; Hasenburg A; Sehouli J; Gropp-Meier M; Schouten PC; Hahnen E; Hauke J; Polleis S; Harter P Int J Gynecol Cancer; 2023 Dec; 33(12):1966-1969. PubMed ID: 37935524 [TBL] [Abstract][Full Text] [Related]
4. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473 [TBL] [Abstract][Full Text] [Related]
5. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695 [TBL] [Abstract][Full Text] [Related]
6. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510 [TBL] [Abstract][Full Text] [Related]
7. Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer. Selle F; Alexandre J; Prulhière K; Kalbacher E; Ray-Coquard I; Leary A; Bull Cancer; 2021 Dec; 108(9S1):S5-S12. PubMed ID: 34955161 [TBL] [Abstract][Full Text] [Related]
8. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312 [TBL] [Abstract][Full Text] [Related]
9. A systematic overview of chemotherapy effects in ovarian cancer. Högberg T; Glimelius B; Nygren P; Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940 [TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751 [TBL] [Abstract][Full Text] [Related]